Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Elamipretide / SS-31.

Research draft

Elamipretide, also called SS-31, is a mitochondria-targeting tetrapeptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Elamipretide, also called SS-31, is a mitochondria-targeting tetrapeptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFO4 amino acids
PRIMARY CONTEXTMitochondria-targeted tetrapeptide

Mechanism

It binds cardiolipin in the inner mitochondrial membrane and affects mitochondrial structure and function.

Human research

It has disease-specific clinical research. FDA accelerated approval for Barth syndrome is based on a surrogate strength measure, with confirmatory research required.

Preclinical & other research

Laboratory and animal work investigated mitochondrial dysfunction across several disease models.

Safety & unknowns

Injection-site reactions and hypersensitivity are relevant. Disease-specific evidence does not establish general anti-ageing benefit.

Regulatory status

Forzinity received US accelerated approval for Barth syndrome in patients weighing at least 30 kg; this does not approve unrelated research vials.

Reported use & evidence

Research profile draft

The supplied Elamipretide / SS-31 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds